Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
54.48
+0.46 (0.85%)
At close: Apr 28, 2026, 4:00 PM EDT
55.00
+0.52 (0.95%)
After-hours: Apr 28, 2026, 4:33 PM EDT
Monopar Therapeutics Employees
Monopar Therapeutics had 22 employees as of December 31, 2025. The number of employees increased by 6 or 37.50% compared to the previous year.
Employees
22
Change (1Y)
6
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$623,495
Market Cap
364.59M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 22 | 6 | 37.50% | 22 | 0 |
| Dec 31, 2024 | 16 | 6 | 60.00% | 14 | 2 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 9 | 1 |
| Dec 31, 2022 | 12 | 2 | 20.00% | 11 | 1 |
| Dec 31, 2021 | 10 | 0 | - | 9 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Bicycle Therapeutics | 288 |
| Nautilus Biotechnology | 130 |
| Silence Therapeutics | 88 |
| X4 Pharmaceuticals | 45 |
| DiaMedica Therapeutics | 35 |
| Avalo Therapeutics | 33 |
| Opus Genetics | 28 |
MNPR News
- 9 days ago - Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 - GlobeNewsWire
- 4 weeks ago - Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer - GlobeNewsWire
- 5 months ago - Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments - GlobeNewsWire
- 6 months ago - Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 - GlobeNewsWire
- 6 months ago - Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 - GlobeNewsWire
- 7 months ago - Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 7 months ago - Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients - GlobeNewsWire